The correlation of extent and grade of inflammation with serum PSA levels in patients with IV prostatitis.
OBJECTIVE
The inflammation was categorized more profoundly, using the standardized histopathological classification system for chronic prostatitis of NIH, to determine the influence of prostatic inflammation on serum PSA levels.


METHODS
The study included 120 patients who underwent transperineal ultrasound-guided prostate biopsy. The patients were divided into groups using 3 grades for the extent, the location and the aggressiveness of prostate inflammation. The serum tPSA levels, fPSA levels, %fPSA, and PSAD in each group were compared.


RESULTS
Of 120 patients, 80 with benign prostatic tissue in their biopsy specimens met the inclusion criteria, excluding 40 cases with prostate cancer. The inflammation was present in 46(57.5%) of 80 cases. The extent of inflammation correlated positively with the total PSA level (r = 0.6, P < 0.001), fPSA (r = 0.5, P = 0.001) and PSAD (r = 0.6, P < 0.001). The grade of inflammation correlated positively with the total PSA level (r = 0.5, P < 0.001), fPSA (r = 0.4, P = 0.008) and PSAD (r = 0.7, P < 0.001). A negative correlation was found between the grade of inflammation and %fPSA (r = -0.4, P = 0.013).


CONCLUSIONS
If the elevation of serum PSA is thought to be caused by asymptomatic prostatitis with high aggressiveness score in BPH patients without clinical prostatitis, it might prevent unnecessary repeated biopsies.
Gui-Zhong
Li
L
Department of Urology, Beijing Jishuitan Hospital, 100035 Beijing, China.
Libo
Man
M
Guanglin
Huang
H
Jianwei
Wang
W
D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood*; D011472:Prostatitis / Q000097:blood* / Q000473:pathology; D012720:Severity of Illness Index
D017430:Prostate-Specific Antigen
Urol Int. 2008;80(2):186-92
18362491
Eur Urol. 2000 Apr;37(4):404-12
10765070
Urol Int. 2003;71(2):160-4
12890953
J Urol. 2000 Sep;164(3 Pt 1):722-5
10953133
Prostate Cancer Prostatic Dis. 2008;11(2):148-52
17637759
Urology. 2007 Oct;70(4):743-7
17991548
Cytokine. 2008 Aug;43(2):194-9
18572414
Urology. 2002 Dec;60(6 Suppl):5-6; discussion 6-7
12521577
Urology. 2003 Nov;62(5):854-9
14624908
Eur Urol. 2008 Dec;54(6):1379-84
18036719
J Urol. 1991 May;145(5):984-7
2016815
Int Urol Nephrol. 2007;39(3):859-63
17111077
J Urol. 1999 Aug;162(2):293-306
10411025
Int Urol Nephrol. 2004;36(4):549-53
15787334
Urology. 2009 Aug;74(2):340-4
19464042
Urology. 2004 Dec;64(6):1098-101
15596176
J Urol. 1998 Apr;159(4):1234-7
9507843
Am J Surg Pathol. 1992 Oct;16(10):975-81
1415905
Urology. 2008 Dec;72(6):1194-7
18829081
Cancer. 1991 Oct 1;68(7):1592-9
1716510
Eur Urol. 2000 May;37(5):537-40
10765091
Curr Urol Rep. 2009 Jul;10(4):302-6
19570492
Cancer. 1996 May 15;77(10):2162-6
8640686
J Urol. 1997 Apr;157(4):1301-3
9120926